2. Gene
  3. Cat - catalase Gene

Cat - catalase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Rattus norvegicus

同用名: CS1; Cas1; Catl; Cs-1; Cat01

基因 ID: 24248 | 基因类型: protein coding

关于 Cat

功能概要

Enables catalase activity. Involved in several processes, including hydrogen peroxide catabolic process; response to ozone; and response to vitamin. Located in several cellular components, including Golgi apparatus; mitochondrial intermembrane space; and peroxisome. Used to study Bacterial pneumonia; brain ischemia; cholestasis; colitis; and lung disease. Biomarker of several diseases, including artery disease (multiple); auditory system disease (multiple); end stage renal disease; eye disease (multiple); and neurodegenerative disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including acatalasia; eye disease (multiple); lung disease (multiple); osteonecrosis; and pseudoxanthoma elasticum. Orthologous to human CAT (catalase). [provided by Alliance of Genome Resources, Apr 2022]

Cat 基因产物(1)

mRNA Protein Name
NM_012520.2 NP_036652.1 catalase
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables catalase activity IDA
IDA: 通过直接分析推断
3455767 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in cellular response to growth factor stimulus IEP
IEP: 通过表达模式推断
21276205 RGD
involved in hydrogen peroxide catabolic process IDA
IDA: 通过直接分析推断
17576767 RGD
involved in hydrogen peroxide catabolic process IMP
IMP: 通过突变表型推断
14713308 RGD
involved in kidney development IMP
IMP: 通过突变表型推断
22733796 RGD
involved in negative regulation of apoptotic process IMP
IMP: 通过突变表型推断
10569634 RGD
involved in response to L-ascorbic acid IEP
IEP: 通过表达模式推断
20698742 RGD
involved in response to UV IEP
IEP: 通过表达模式推断
12592055 RGD
involved in response to activity IEP
IEP: 通过表达模式推断
9250541 RGD
involved in response to amitrole IEP
IEP: 通过表达模式推断
7195942 RGD
involved in response to cadmium ion IEP
IEP: 通过表达模式推断
18655190 RGD
involved in response to estradiol IEP
IEP: 通过表达模式推断
25038876 RGD
involved in response to ethanol IEP
IEP: 通过表达模式推断
9250541 RGD
involved in response to fatty acid IEP
IEP: 通过表达模式推断
23232760 RGD
involved in response to hyperoxia IEP
IEP: 通过表达模式推断
19895324 RGD
involved in response to hypoxia IMP
IMP: 通过突变表型推断
18270324 RGD
involved in response to inactivity IEP
IEP: 通过表达模式推断
15638087 RGD
involved in response to insulin IEP
IEP: 通过表达模式推断
20465785 RGD
involved in response to lead ion IEP
IEP: 通过表达模式推断
15721881 RGD
involved in response to light intensity IEP
IEP: 通过表达模式推断
17514533 RGD
involved in response to oxidative stress IDA
IDA: 通过直接分析推断
17576767 RGD
involved in response to ozone IEP
IEP: 通过表达模式推断
20465785 RGD
involved in response to phenylpropanoid IEP
IEP: 通过表达模式推断
18547798 RGD
involved in response to reactive oxygen species IMP
IMP: 通过突变表型推断
14713308 RGD
involved in response to toxic substance IEP
IEP: 通过表达模式推断
12225545 RGD
involved in response to vitamin A IEP
IEP: 通过表达模式推断
23485553 RGD
involved in response to vitamin E IEP
IEP: 通过表达模式推断
19641679 RGD
involved in response to xenobiotic stimulus IEP
IEP: 通过表达模式推断
16131024 RGD
involved in ureteric bud development IMP
IMP: 通过突变表型推断
22733796 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in extracellular space IDA
IDA: 通过直接分析推断
9250541 RGD
located in peroxisomal matrix IDA
IDA: 通过直接分析推断
26961980 RGD
located in peroxisome IDA
IDA: 通过直接分析推断
14561759 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

catalase

相关产品

Approval
生物活性分子 (29)
目录号 产品名 作用方式
纯度 是否罕见病
HY-B0988 Deferoxamine mesylate 99.94% 否
HY-B1625 Deferoxamine 99.76% 是
HY-Y0682 Ethylenediaminetetraacetic acid ≥98.0% 否
HY-B0193A Prazosin hydrochloride 99.51% 否
HY-75161 (-)-Menthol Activator 99.79% 否
HY-P0163 Gramicidin Inhibitor 98.0% 否
HY-B1221 Flufenamic acid 99.93% 否
HY-B1836 Meldonium Activator 99.82% 否
HY-N7075 Inulin / 是
HY-B1203A Fludrocortisone acetate 99.59% 否
HY-A0066A Tolazoline hydrochloride Antagonist 99.93% 否
HY-B1213 Trimipramine maleate 99.82% 否
HY-Y0682A Ethylenediaminetetraacetic acid disodium dihydrate 99.9% 否
HY-B0565 Ronidazole Inhibitor 99.48% 否
HY-109556 Insulin Detemir Activator 95.0% 否
HY-Y0682B Ethylenediaminetetraacetic acid tetrasodium 98.0% 否
HY-119572 Sodium zirconium cyclosilicate 95.0% 否
HY-B1836A Meldonium dihydrate Activator 99.0% 否
HY-B1833 Afloqualone Agonist 99.94% 否
HY-103354 Proglumide sodium Antagonist 99.58% 是
HY-B1330 Proglumide Antagonist 99.84% 是
HY-B1009 Ethylenediaminetetraacetic acid trisodium salt 98.0% 否
HY-B2143 Montmorillonite ≥98.0% 否
HY-W014332 1,3-Diphenylguanidine 99.76% 否
HY-118874 Oblimersen / 否
HY-103354A Proglumide hemicalcium Antagonist / 否
HY-16094 Bethanidine sulfate Antagonist / 否
HY-B0193AR Prazosin hydrochloride (Standard) / 否
HY-B1213A Trimipramine / 否
抗体抑制剂 (1)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P99053 Tralokinumab Inhibitor 99.12% 否
Clinical Phase
生物活性分子 (16)
目录号 产品名 作用方式
纯度 Phase
HY-N6687 Calcimycin 99.12% Phase 4
HY-B0762 Acetyl-L-carnitine hydrochloride Inhibitor 99.95% Phase 4
HY-113218 Acetyl-L-carnitine Inhibitor 99.86% Phase 4
HY-W105700 Ethylenediaminetetraacetic acid sodium hydrate 98.0% Phase 4
HY-N6687A Calcimycin hemicalcium salt / Phase 4
HY-N6687B Calcimycin hemimagnesium / Phase 4
HY-103586 GS-441524 Inhibitor 99.89% Phase 3
HY-142118 Trabedersen Inhibitor 90.45% Phase 3
HY-145728 Alicaforsen Inhibitor / Phase 3
HY-114671 Taprostene Agonist / Phase 3
HY-P2141A TRV-120027 TFA Agonist 99.69% Phase 2
HY-A0157B Dimethothiazine hydrochloride Antagonist / Phase 2
HY-P10515 AcrAP2 Inhibitor / Phase 2
HY-15533 LY 3000328 Inhibitor 99.50% Phase 1
HY-100973A Adenosine 5′-diphosphoribose sodium 99.47% Phase 1
HY-103586A GS-441524 hydrochloride Inhibitor / Phase 1
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 Phase
HY-P99305 Metelimumab Inhibitor 98.98% Phase 2
HY-P99474 Bertilimumab Inhibitor 97.01% Phase 2
Pre-clinical Phase
生物活性分子 (216)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-13434 Ionomycin 99.27% 否
HY-P1410 GsMTx4 Inhibitor 99.83% 否
HY-101840 EIPA 99.73% 否
HY-13434A Ionomycin calcium 98.02% 否
HY-152182 ML-SA5 Agonist 99.69% 否
HY-146245 ODN 1826 99.69% 否
HY-P1410A GsMTx4 TFA Inhibitor 99.85% 否
HY-112540B Acetoacetic acid sodium 98.0% 否
HY-129555 Surfactin Inhibitor 98.96% 否
HY-101840A EIPA hydrochloride 98.31% 否
HY-P1471 Adrenomedullin (AM) (22-52), human Antagonist 99.61% 否
HY-B1793 Tetraethylammonium chloride Inhibitor 98.0% 否
HY-W011527 Xanthosine 99.96% 否
HY-112540A Acetoacetic acid lithium 98.0% 否
HY-14710 AZ3146 Inhibitor 99.42% 否
HY-19960 BCTC 99.66% 否
HY-125623 MitoPerOx 98.14% 否
HY-Y1881B Copper sulfate pentahydrate, for cell culture, 98% 98.00% 否
HY-100231 Cathepsin inhibitor 1 Inhibitor 99.28% 否
HY-19408 Pyr10 Inhibitor 99.95% 否
HY-113486 Lathosterol 98.09% 否
HY-113469 Cyclic GMP 99.77% 否
HY-150726 ODN 1668 98.79% 否
HY-120601 Alizarin Red S sodium 95.0% 否
HY-P2141 TRV-120027 Agonist 98.11% 否
HY-128483 Fusaric acid 99.94% 否
HY-W013579 (S)-(+)-Carvone 99.26% 否
HY-135869 Mito-apocynin (C11) Inhibitor 99.84% 否
HY-D0193 Ponceau 4R 99.84% 否
HY-107740 Pseudoisocyanine iodide Inhibitor 99.97% 否
HY-113469A Cyclic GMP sodium 99.89% 否
HY-32350 Ercalcitriol Activator 99.42% 否
HY-122605 TRPM4-IN-1 Inhibitor 99.98% 否
HY-129096 IDT307 99.76% 否
HY-Y1881A Copper sulfate pentahydrate, 99.9% 99.90% 否
HY-N1378 (E)-Cardamonin 99.84% 否
HY-110374 NVS-CECR2-1 99.40% 否
HY-B0762S1 Acetyl-L-carnitine-d3-1 hydrochloride Inhibitor 99.12% 否
HY-P5601A Thanatin TFA Inhibitor 99.68% 否
HY-146584 Cathepsin C-IN-5 Inhibitor 95.70% 否
HY-144256 CHD1Li 6.11 99.54% 否
HY-19976 RN-1747 Agonist 99.27% 否
HY-B0927 Hydrastine Inhibitor 99.57% 否
HY-P2324 Gramicidin A Inhibitor 98.10% 否
HY-108460 A-784168 Inhibitor 99.0% 否
HY-112776A BN82002 hydrochloride Inhibitor 99.36% 否
HY-W018574 Tetraoctylammonium bromide 98.0% 否
HY-P2887 Acetate kinase (ACK) / 否
HY-W014106 Tetraethylammonium tetrafluoroborate ≥98.0% 否
HY-B1827 D-Galacturonic acid hydrate 99.92% 否
HY-160610A Carbamoyl phosphate dilithium salt / 否
HY-121065 BN-82685 Inhibitor 99.05% 否
HY-131897 1-Stearoyl-2-arachidonoyl-sn-glycerol Activator 99.0% 否
HY-N2003 D-Tetrahydropalmatine Antagonist 99.84% 否
HY-B0762S Acetyl-L-carnitine-d3 hydrochloride Inhibitor 99.79% 否
HY-P1077A CALP1 TFA 99.86% 否
HY-17630 Edasalonexent Inhibitor 99.17% 是
HY-139192 Brophenexin 99.59% 否
HY-Y0682S Ethylenediaminetetraacetic acid-d12 98.00% 否
HY-133825 Cyazofamid Inhibitor 98.15% 否
HY-107535 AS1269574 99.84% 否
HY-N6790 Nonactin 99.0% 否
HY-125870 Gellan gum, for cell culture 97.0% 否
HY-W006212 1,4,7-Triazonane 99.62% 否
HY-135868 Mito-apocynin (C2) Inhibitor 98.38% 否
HY-171152A NSC 357754 dihydrochloride Inhibitor 98.01% 否
HY-P1770 Adrenomedullin (16-31), human 98.50% 否
HY-W025784 Kalibor 99.62% 否
HY-147774 Cathepsin K inhibitor 6 Inhibitor 98.18% 否
HY-76632 4-Hydroxyisophthalic acid Activator 99.51% 否
HY-148129 Apecotrep Inhibitor 99.17% 否
HY-117865 GNE-886 Inhibitor 99.81% 否
HY-139192A Brophenexin free base 99.24% 否
HY-149203A MQA-P TFA 97.36% 否
HY-E70373 λ Protein phosphatase / 否
HY-W011087 Benzyldimethyltetradecylammonium chloride 99.70% 否
HY-W011972 Bromocholine bromide 98.0% 否
HY-112540 Acetoacetic acid 95.0% 否
HY-W103463 1-Phenyl-2-pyrrolidinone Inhibitor 99.86% 否
HY-12761 A-836339 Agonist 99.84% 否
HY-113469B Cyclic GMP (TBAOH) 99.07% 否
HY-10656 SB-657510 Antagonist 99.84% 否
HY-108446 GSK 1562590 hydrochloride Antagonist 99.0% 否
HY-109077 Tigolaner 98.53% 否
HY-111527 PPZ2 99.92% 否
HY-112776 BN82002 Inhibitor / 否
HY-158222A Alginate Methacryloyl (MW 300000) / 否
HY-B1221S1 Flufenamic acid-13C6 99.5% 否
HY-W014408 Tetraethylammonium bromide ≥98.0% 否
HY-W015815 6-Methylnicotinamide 99.98% 否
HY-W753904 Pradofloxacin Inhibitor 98.02% 否
HY-158222 Alginate Methacryloyl (MW 50000) / 否
HY-171152 NSC 357754 Inhibitor / 否
HY-111297 BMVC4 / 否
HY-137155 Dapsone hydroxylamine Inhibitor 94.92% 否
HY-145150 TRPC5-IN-1 Inhibitor 98.97% 否
HY-153613 Ac-PLVE-FMK Inhibitor 98.0% 否
HY-155254 Sodium ionophore VI 98.0% 否
HY-B1827R D-Galacturonic acid hydrate (Standard) / 否
HY-E70191 β-1,4-Galactosyltransferase 2 / 否
HY-E70387 Ligninase / 否
HY-P1077 CALP1 98.44% 否
HY-W011052 Tetrapentylammonium bromide 98.0% 否
HY-W012450 Trimethylphenylammonium bromide 98.0% 否
HY-W014536 N,N,N-Trimethyloctan-1-aminium chloride 99.0% 否
HY-W016638 1-Butyl-1-methylpyrrolidinium chloride ≥98.0% 否
HY-W127701 [Bmpip][NTf2] ≥97.0% 否
HY-W127739 Zineb / 否
HY-N8707 Homobutein Inhibitor 98.35% 否
HY-RS29475 CEPT1 Human/Cat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W013264A Tetrabutylammonium chloride monohydrate 97.0% 否
HY-W587415 cis/trans-Nepetalactol 95.0% 否
HY-W739372 Poly(sodium 4-styrenesulfonate) / 否
HY-W781133 cDPCP 99.9% 否
HY-100057 BMY 28674 Antagonist / 否
HY-103216A RWJ52353 hydrochloride Agonist / 否
HY-107129 MK-3577 Antagonist / 否
HY-107345 Droxicam Inhibitor / 否
HY-107644 AQ-RA 741 Antagonist / 否
HY-107756 LOE 908 hydrochloride Inhibitor / 否
HY-111525 Monactin Inhibitor / 否
HY-113486R Lathosterol (Standard) / 否
HY-113486S1 lathosterol-d7 / 否
HY-113778 15-keto-17-phenyl trinor Prostaglandin F2α / 否
HY-115371 Butaperazine dimaleate / 否
HY-116161 Bimatoprost isopropyl ester / 否
HY-116264 CatB-IN-1 / 否
HY-116478 L-3373 Inhibitor / 否
HY-117774 AHR-2244 hydrochloride / 否
HY-117817 Ranelic acid / 否
HY-120685 WAY-125971 Antagonist / 否
HY-121670 Ambenoxan / 否
HY-121670A Ambenoxan hydrochloride / 否
HY-124514 UC-857993 Inhibitor / 否
HY-126115 15(S)-Latanoprost Inhibitor / 否
HY-126763 ATI22-107 Inhibitor / 否
HY-129846 IBTP iodide / 否
HY-131897S 1-Stearoyl-2-Arachidonoyl-d8-sn-Glycerol Activator / 否
HY-136894 Rhod-5N / 否
HY-143714 Cathepsin K inhibitor 2 Inhibitor / 否
HY-146580 Cathepsin C-IN-3 Inhibitor / 否
HY-146581 Cathepsin C-IN-4 Inhibitor / 否
HY-147186 5,5'-Difluoro BAPTA / 否
HY-147333 Trimipramine N-oxide / 否
HY-148156 Hydroxydione Inhibitor / 否
HY-148162 Kayexalate / 否
HY-153614 Ac-VLPE-FMK Inhibitor 99.0% 否
HY-156045A Cross-linked dextran G 10 / 否
HY-157441 AChE/Aβ-IN-4 Inhibitor / 否
HY-157915 HFPB / 否
HY-161772 (S)-Gebr32a Inhibitor / 否
HY-171837A t9,t11,c15-CLNA / 否
HY-172342 MitoA bromide / 否
HY-172387 CM Cross-linked dextran C 25 / 否
HY-172387A CM Cross-linked dextran C 50 / 否
HY-175498 RLA-3107 Inhibitor / 否
HY-A0157 Dimethothiazine Antagonist / 否
HY-A0157A Dimethothiazine mesylate Antagonist / 否
HY-B0565S Ronidazole-d3 Inhibitor / 否
HY-B0762R Acetyl-L-carnitine hydrochloride (Standard) Inhibitor 99.95% 否
HY-B1221S Flufenamic acid-d4 / 否
HY-B1827A D-Galacturonic acid / 否
HY-D1640 5',5-Difluoro BAPTA tetrapotassium / 否
HY-N14351 Ferrocin A Inhibitor / 否
HY-N15626 Speciophylline / 否
HY-N7857 19(R)-Hydroxy-prostaglandin F2α / 否
HY-P10228 S-Thanatin Inhibitor / 否
HY-P10652 hsBCL9CT-24 Inhibitor / 否
HY-P1471A Adrenomedullin (AM) (22-52), human TFA Antagonist / 否
HY-P1770A Adrenomedullin (16-31), human TFA / 否
HY-P2324A Gramicidin A TFA Inhibitor / 否
HY-P3711 SPAI-1 Inhibitor / 否
HY-P5601 Thanatin Inhibitor / 否
HY-P5898 Z-Val-Val-Nle-diazomethylketone Inhibitor / 否
HY-RS01982 CAT Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS03139 CRAT Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS05510 GLYAT Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-W010736A 1,2-Dipalmitoyl-rac-glycerol / 否
HY-W011122 Tributylbenzylammonium bromide 98.0% 否
HY-W013231 N-Benzyl-N,N-diethylethanaminium iodide / 否
HY-W075836 Ferrocenylmethyltrimethylammonium iodide / 否
HY-W105699 EDTA tetrasodium tetrahydrate 97.0% 否
HY-W654000 Cyclic GMP-13C,15N2 / 否
HY-W711474 (-)-Menthol-d4 / 否
HY-W724370 Tetraethylammonium bromide-d20 / 否
HY-W765177 Acetyl-L-carnitine hydrochloride-13C3 / 否
HY-W767865 Cyclic GMP sodium-13C5 / 否
HY-W777365 Ethylenediaminetetraacetic acid-13C4 / 否
HY-Y0682S1 Ethylenediaminetetraacetic acid-d16 / 否
HY-106699 Taprostene sodium Agonist / 否
HY-116889 15-Keto latanoprost acid / 否
HY-120601A Alizarin Red S / 否
HY-124894 (+)-Benalaxyl Inhibitor / 否
HY-126605 Trinactin Inhibitor / 否
HY-130325 α-Guanidinoglutaric acid Inhibitor / 否
HY-134268 8-Br-7-CH-ADPR Antagonist / 否
HY-137639 Sp-8-Br-cGMPS Agonist / 否
HY-139120 19(R)-hydroxy Prostaglandin E2 / 否
HY-148034 Plm IV inhibitor-1 Inhibitor / 否
HY-14830 SAR 97276 Inhibitor 98.05% 否
HY-157240 CEX Ion-exchange resin / 否
HY-157241 CEX Cation-exchange resin 1 / 否
HY-157242 CEX Polishing resin / 否
HY-157243 CEX Cation-exchange resin 2 / 否
HY-163073 Anti-MRSA agent 9 Inhibitor / 否
HY-168363 Ciclotizolam Ligand / 否
HY-170993 Antimicrobial agent-39 Inhibitor / 否
HY-175862 ALR2-IN-9 / 否
HY-N9928 Echinenone Inhibitor / 否
HY-RS16665 Cat Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS16943 Trpv6 Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS19300 Mip Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS23100 Cat Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W108381 Pyriprole / 否
HY-W654254 Malachite green-d5 oxalate / 否
HY-10290 MK-0674 Inhibitor / 否
抗体抑制剂 (3)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99627 Frunevetmab 95.00% 否
HY-P99695 Lerdelimumab Inhibitor / 否
HY-P990562 CAT-2200 / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Cat NCBI NCBI:847
Felis catus Cat NCBI NCBI:101093891
Canis lupus familiaris Cat NCBI
Mus musculus Cat NCBI NCBI:12359
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z